Xoten A 10 Capsule contains a combination of Rosuvastatin 10 mg and Aspirin 75 mg, formulated to provide dual therapeutic benefits in cardiovascular risk management. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels, thereby reducing the risk of atherosclerosis and related cardiovascular events. Aspirin, an antiplatelet agent, inhibits cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 production and subsequent platelet aggregation inhibition, which helps prevent thrombus formation. This combination is indicated for patients at high risk of cardiovascular diseases, including those with a history of myocardial infarction, stroke, or established coronary artery disease, to reduce the incidence of major cardiovascular events. Xoten A 10 Capsule should be administered as prescribed by a healthcare professional, typically once daily, with or without food. Regular monitoring of lipid profiles, liver function tests, and platelet counts is recommended during therapy to ensure efficacy and safety. Caution is advised in patients with active bleeding, liver impairment, or hypersensitivity to either component. This combination therapy offers a comprehensive approach to managing hyperlipidemia and thrombosis risk, contributing to improved cardiovascular outcomes.